IP Library Granted Patent US 11,571,187
Granted Patent B2
US 11,571,187 · App. 16/683,939 · Granted Feb 7, 2023

Method for obtaining sterile human amniotic fluid and uses thereof

Inventor: Carl Randall Harrell (Tarpon Springs, FL)
Assignee: MAM HOLDINGS OF WEST FLORIDA, L.L.C.
A61B10/0048A61B8/0841A61L2/081A61L2/087A61M1/0011A61B10/0233A61B10/0283A61M2202/0437A61M2202/0494
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,571,187
App. No.
16/683,939
Granted
Feb 7, 2023
Kind
B2
Abstract

Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells. Also provided is the sterile amniotic fluid or filtrates thereof collected by the method described herein.

Claims (15)

1. A method for enhancing wound healing, cosmetic, orthopedic, or ophthalmic applications, comprising:

administering an effective amount of a sterile filtered, cell-free, non-irradiated human amniotic fluid to a site in need thereof;

wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid comprises serially filtered human amniotic fluid prepared by a process comprising:

collecting amniotic fluid under sterile conditions from a woman;

removing cells, large particles, and other undissolvables from the human amniotic fluid by centrifuging the human amniotic fluid to obtain clarified amniotic fluid; and

serially filtering the clarified amniotic fluid through multiple filters selected from the group consisting of depth filters and membrane filters with a pore size of 0.45 μm and 0.2 μm to obtain a sterile filtrate that is not irradiated.

2. The method of claim 1 , wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid has a 10 6 sterility assurance level.

3. The method of claim 1 , wherein the ophthalmic application is for treating dry eyes in a human.

4. The method of claim 3 , wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid is in an amount effective to decrease corneal inflammation associated with dry eyes.

5. The method of claim 1 , wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid is sterilely packaged into syringes or vials suitable for administration.

6. The method of claim 1 , wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid has been lyophilized and formulated for administration to the site in need thereof, optionally in combination with a reconstituting or dissolution agent.

7. The method of claim 3 , wherein the sterile filtered, cell-free, non-irradiated human amniotic fluid has been lyophilized and formulated for administration to dry eyes, optionally in combination with a reconstituting or dissolution agent.

8. The method of claim 6 or claim 7 , wherein the lyophilizate of amniotic fluid is sterilely packaged into vials ready for reconstitution into a fluid.

9. The method of claim 6 or claim 7 , wherein the reconstituting or dissolution agent is sterile water.

10. The method of claim 1 , wherein the site in need thereof is a wound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2019
From: HARRELL, CARL RANDALL
To: MAM HOLDINGS OF WEST FLORIDA, L.L.C.
Reel/Frame 051021/0308 →
Continuity (4)
Continuation 14508578 · Oct 7, 2014
Continuation In Part 14275086 · May 12, 2014
Provisional Application 61821868 · May 10, 2013
Related Publication 20200077987A1 · Mar 12, 2020